Quick Answer
GT Biopharma, Inc. reported Net Income of -$28.35 million for fiscal year 2025.
GT Biopharma, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$28.35M | -115.4% |
| 2024 | -$13.16M | -73.3% |
| 2023 | -$7.60M | +63.6% |
| 2022 | -$20.88M | +64.0% |
| 2021 | -$58.01M | -105.0% |
| 2020 | -$28.30M | +26.8% |
| 2019 | -$38.65M | +85.1% |
| 2018 | -$259.19M | -79.8% |
| 2017 | -$144.17M | -1576.0% |
| 2016 | $9.77M | +129.8% |
| 2015 | -$32.73M | -39.3% |
| 2014 | -$23.49M | -4588.4% |
| 2013 | -$501.0K | +90.3% |
| 2012 | -$5.17M | -39.8% |
| 2011 | -$3.70M | -23.5% |
| 2010 | -$3.00M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$3.11M | +8.7% | -117.3% |
| June 30, 2025 | -$1.43M | +61.4% | -84.7% |
| March 31, 2025 | -$776.0K | +65.8% | +77.3% |
| September 30, 2024 | -$3.41M | -41.2% | +8.1% |
| June 30, 2024 | -$3.71M | -86.2% | -63.7% |
| March 31, 2024 | -$2.27M | -898.2% | +6.2% |
| September 30, 2023 | -$2.42M | +64.9% | -21.3% |
| June 30, 2023 | -$1.99M | +33.1% | -777.5% |
- GT Biopharma, Inc. showed a decrease of -115.4% in Net Income compared to the prior fiscal year.
- Over the 2010–2025 period, GT Biopharma, Inc.’s net income has declined by 846.7% (from -$3.00 million to -$28.35 million).
- The most recent figure is from GT Biopharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: